Clinical Trials

466 enrolled

Ovarian Neoplasms

NCT06459180 2026-03-13

TroFuse-020

686 enrolled

Uterine Cervical Neoplasms

NCT06203210 2026-03-02

IDeate-Lung02

540 enrolled

Small Cell Lung Carcinoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

750 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT04322318 2026-02-24

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

256 enrolled

Genitourinary

Wilms Tumor

NCT06647953 2026-02-24

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

110 enrolled

Pleuropulmonary blastoma

NCT05535166 2026-02-12

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

130 enrolled

CNS

Brain Neoplasms, Medulloblastoma

NCT06528496 2026-02-10

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

45 enrolled

CNS

Neuroblastoma

NCT06930755 2026-01-21

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Phase 1 Recruiting

24 enrolled

Ovarian Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT07218809 2026-01-16

TREVI-OC-01

1,100 enrolled

Carcinoma, Ovarian Epithelial

NCT06161025 2026-01-12

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

860 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07189455 2026-01-05

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

420 enrolled

Small Cell Lung Carcinoma

NCT06855069 2025-12-17

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

468 enrolled

Ovarian Neoplasms

NCT05521984 2025-12-08

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Phase 1 Recruiting

20 enrolled

Pediatric Brain Tumor

NCT04681417 2025-11-28

RETINO 2018

Phase 2/3 Recruiting

225 enrolled

Retinoblastoma

NCT05874401 2025-09-04

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Phase 4 Recruiting

302 enrolled

Other hematologic neoplasm

Small Cell Lung Carcinoma

NCT05101551 2025-05-29

PARPAML

Phase 1 Recruiting

34 enrolled

Leukemia, Myeloid, Acute

NCT06972602 2025-05-15

High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed

Phase EARLY_PHASE1 Recruiting

10 enrolled

Recurrence, Retinoblastoma

NCT05800587 2025-04-04

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

280 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06612151 2025-02-11

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

438 enrolled

Small Cell Lung Carcinoma

NCT06616532 2024-12-19

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

404 enrolled

SCLC

NCT06496048 2024-12-12

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

180 enrolled

Small Cell Lung Carcinoma

NCT06498479 2024-10-16

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

460 enrolled

Small Cell Lung Carcinoma

NCT06394492 2024-08-09

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

440 enrolled

Ovarian Neoplasms

NCT06128837 2024-03-15

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

686 enrolled

Small Cell Lung Carcinoma

NCT04799002 2021-03-16

Topotecan and Melphalan for Retinoblastoma

50 enrolled